Funding round
RemeGen Growth
Reported as "Growth Equity"
RemeGen, a pharmaceutical products company in Yantai, raised $100M in a Growth round announced on 2 Apr 2020, led by Lilly Asia Ventures and Lake Bleu Capital. 8 firms took part.
$100M
Amount raised
Not disclosed
Post-money valuation
8
Investors
2 leads
Valuation
What this round says about the price
RemeGen did not disclose a valuation in this round. It is RemeGen's first venture round on record, 12 years after it was founded in 2008. No later venture round is on record for RemeGen.
RemeGen's funding rounds
This is the only venture round on record for RemeGen.
- Growth this round 2 Apr 2020, led by Lilly Asia Ventures and Lake Bleu Capital $100M
- Other not a venture round 1 Jan 2026 $650M
Investors
Who put money in
Lilly Asia Ventures and Lake Bleu Capital led the round with 6 other firms.
Lead investors
- Lilly Asia Ventures new investor
- Lake Bleu Capital new investor
Also in the round
- backs 36 venture-backed companies new investor
- backs 2 venture-backed companies new investor
- backs 93 venture-backed companies new investor
- backs 4 venture-backed companies new investor
- Loyal Valley Capital new investor
- China Reform Conson Soochow Overseas Fund new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development, sales and marketing, scaling operations and working capital.
- Product development
- Sales and marketing
- Scaling operations
- Working capital
Comparable rounds
How it compares
15 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $77M, and this round was 1.3 times the median. The closest in time, other companies' Growth rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Pharmaceutical Products | 10 Mar 2020 | $35M | not disclosed | Bupa Australia and Federation Asset Management |
| Pharmaceutical Products | 28 Jan 2020 | $200M | not disclosed | not named |
| Cerevel Pharmaceutical Products | 27 Oct 2020 | $440M | not disclosed | Perceptive Advisors |
| Nimbus Therapeutics Pharmaceutical Products | 14 Oct 2020 | $60M | not disclosed | RA Capital |
| Pharmaceutical Products | 4 Sep 2019 | $66M | not disclosed | ADM Capital |
| Sanfer Pharmaceutical Products | 19 Aug 2019 | $500M | not disclosed | La Caisse |
| Pharmaceutical Products | 16 Jul 2019 | $130M | $783M | EQT and Andera Partners |
| Pharmaceutical Products | 11 Jul 2019 | $32M | not disclosed | Sofinnova Partners and Bpifrance |
Sources
Where this comes from
Reported by 2 sources. The deal data marks this round as not yet confirmed by an official announcement. Unconfirmed
Questions
Frequently asked
How much did RemeGen raise in its Growth round?
RemeGen raised $100M in its Growth round, announced in Apr 2020.
Who led RemeGen's Growth round?
Lilly Asia Ventures and Lake Bleu Capital led it, with Vivo Capital, Janchor Partners, OrbiMed, Hudson Bay Capital and Loyal Valley Capital and 1 more.
What was RemeGen's valuation at the Growth round?
It was not disclosed.
How does it compare with other Growth rounds in Pharmaceutical Products?
15 Growth rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $77M, and this round was 1.3 times the median.